ElectroCore, Inc. Announces Rebate Agreement with Ascent Health Services for gammaCore Preferred Brand Coverage on all Express Scripts Standard National Formularies
January 27, 2020 at 01:00 pm
Share
electroCore, Inc. announced that Ascent Health Services on behalf of Express Scripts has elected to make gammaCoreTM a preferred brand on all of its Standard National Formularies for those benefit designs that do not differentiate between drugs and devices at a monthly co-pay of roughly $25- $45. gammaCore is electroCore’s non-invasive vagus nerve stimulation (nVNS) device that is FDA-cleared for the adjunctive use for the preventive treatment of cluster headache, and the acute treatment of pain associated with cluster and migraine headache in adults. gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy FDA-cleared as an adjunctive therapy for the preventative treatment of cluster headache and as an acute treatment for pain associated with episodic cluster headache and migraine headache in adult patients. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers leading to a modulation of neurotransmitters and a reduction in pain. gammaCore is the only therapy FDA-cleared for the prevention of cluster headache. gammaCore is available by prescription only and patients should speak with their doctor about whether gammaCore is right for them. gammaCore™ (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore is indicated for: Adjunctive use for the preventive treatment of cluster headache in adult patients. The acute treatment of pain associated with episodic cluster headache in adult patients. The acute treatment of pain associated with migraine headache in adult patients. The safety and effectiveness of gammaCore (nVNS) have not been established in the acute treatment of chronic cluster headache. gammaCore has not been shown to be effective for the preventive treatment of migraine headache. The long-term effects of the chronic use of gammaCore have not been evaluated. Safety and efficacy of gammaCore have not been evaluated in the following patients, and therefore it is NOT indicated for: Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device. Patients diagnosed with narrowing of the arteries (carotid atherosclerosis). Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy). Pediatric patients. Pregnant women. Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia. Patients should not use gammaCore if they: Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck. Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone).
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
ElectroCore, Inc. Announces Rebate Agreement with Ascent Health Services for gammaCore Preferred Brand Coverage on all Express Scripts Standard National Formularies